Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?
about
Hepatitis B Reactivation with Novel Agents in Non-Hodgkin's Lymphoma and Prevention StrategiesManagement of chronic hepatitis B before and after liver transplantationPrevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapyHepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-ScreenedViral hepatitis screening guideline before biological drug use in rheumatic patientsHBV-Associated Acute Liver Failure After Immunosuppression and Risk of Death.Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection.Age-dependent decrease of anti-HBs titers and effect of booster doses using 2 different vaccines in Palestinian children vaccinated in early childhood.Seroprevalences of hepatitis B virus and hepatitis C virus among participants of an Asian health fair in the Lower Mainland, British Columbia.Drug-Induced Liver Injury: Pattern Recognition and Future Directions.Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administrationHepatitis B Serology in Patients with Rheumatic DiseasesTreatment of Hepatitis B: A Concise Review.Infections in severe alcoholic hepatitis.Optimizing antiviral agents for hepatitis B management in malignant lymphomas.Occult hepatitis B virus infection in Egypt.Prevention and management of hepatitis B virus reactivation in cancer patients.Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta-analysis.Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders.Treatment of chronic hepatitis B infection-2017.The oncologic burden of hepatitis C virus infection: A clinical perspective.Screening rate for hepatitis B virus infection in patients undergoing chemotherapy in Japan.Gastroenterologists Have Suboptimal Hepatitis B Virus Screening Rates in Patients Receiving Immunosuppressive Therapy.Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis.Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: Analysis of a Japanese prospective cohort.Hepatitis B virus infection is associated with younger median age at diagnosis and death in cancers.Improvements in hepatitis B virus screening before rituximab therapy: A community-based, safety-net hospital experience.No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.The effect of rituximab dose on infectious complications in ABO-incompatible kidney transplantation.Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients With Acute Hepatitis B.Prevention of HBV reactivation in patients treated with biologic agents.Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.Screening for viral hepatitis prior to rituximab chemotherapy.Fatal reactivation of hepatitis B virus infection in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab.HBV Core Protein Enhances Cytokine Production.Black Box Warning for Possible HBV Reactivation During DAA Therapy for Chronic HCV Infection.Editorial Commentary: Another Call to Cure Hepatitis B.
P2860
Q26746486-E1BE4A46-A371-46AB-86A8-C28817D874F9Q27024831-72C86F22-7077-4F50-A411-508CA52C54E7Q28070090-69F8087B-9C6B-4AF4-B7E6-5274B6D94517Q28076703-DCB7AA0B-1B7C-4C92-9E27-822457907E1DQ28076767-776AB92C-90BD-4FC6-A95D-1064B45B5851Q33433133-1B311F7B-2530-4ABA-B96A-6153FEE3E3F2Q33629349-CD5432A2-BBF6-4764-95FE-5764276B31B4Q35887238-9203965F-0342-4822-939C-64BAF76C9174Q36015661-38CD2C65-6172-4597-8D3D-AC138E8FDD48Q36412863-1141F123-3002-4188-B547-ACF2D72A5AB8Q36909250-A73DE4F5-D667-4FDD-9CBC-9642D2970D8FQ37291847-F0B3F20E-D2D0-4805-A52B-B4BE8853715BQ37620340-E9380E26-416D-4F97-846E-F9994D66455BQ37657099-F58D7EAB-8736-40AA-9125-5D545E33A9C5Q37666948-8D8C95B6-6415-469C-96D0-BC7560E02506Q38542377-FE3789F6-4272-4AD1-9CFF-5A8EE5E6286FQ38688782-EB05662B-7572-41F5-99BA-88B54D71E73AQ38755178-B4FAA79C-2A04-4C31-81FE-551ED3C4F135Q38765053-2C48ECCD-28A7-40BA-9DCE-B8B2DB443AE4Q38810735-B488D2EB-08E4-45D2-9F5B-9FBFF43FE8ABQ39067365-B702EF88-FE49-4DE5-BAA9-3A93387F582AQ39418450-B6EAB3A2-B6E0-4BF9-B577-F4594556002CQ39711189-D200081E-2113-40BA-BEEC-1225127AF033Q39906266-2D0DE0D0-D1C9-4D05-9A68-F69BE41C2188Q40045559-E9CC8CFE-A37D-4C85-A17A-AEDCAAD99108Q40081220-566D2777-DB86-4AB3-8235-2F844F7D8E26Q40152808-AA4EFD14-BEE9-4EBF-B13B-13C525458290Q40171284-74269D1E-7C00-4A66-AA9E-3CF8CA0B845AQ40261539-B9481126-3F62-4F26-A700-925D098A2052Q40409921-E63ABBFB-4E33-44AC-A3A7-6C7DD826F362Q40590326-BD55F07A-3380-4114-A7DC-6057A604DE7DQ40670409-67E5E5A2-C4DE-4278-8433-D97E2000A80DQ40779997-CCA12CFD-A479-4AC6-A09C-3D8B2ACB677FQ40830395-25C58F65-0279-4E71-A320-56D3E4719B75Q40870495-1515E1AF-7348-4150-AA0E-B653479F5490Q40993578-C1E33CF1-9CFD-446F-95AC-41AD56B15DCCQ41442058-5A11CB05-34D4-4995-93EA-9C830B765444Q42121965-39AAF31C-84FE-4845-91A7-D335C8E58B8DQ42374435-A08FF5B3-D2DC-4F38-881D-9E6439C5C2F2Q43239619-49FB5780-4C68-4681-ADEA-D76CEA88E9BB
P2860
Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Recent US Food and Drug Admini ...... : just the tip of the iceberg?
@ast
Recent US Food and Drug Admini ...... : just the tip of the iceberg?
@en
type
label
Recent US Food and Drug Admini ...... : just the tip of the iceberg?
@ast
Recent US Food and Drug Admini ...... : just the tip of the iceberg?
@en
prefLabel
Recent US Food and Drug Admini ...... : just the tip of the iceberg?
@ast
Recent US Food and Drug Admini ...... : just the tip of the iceberg?
@en
P2093
P2860
P356
P1433
P1476
Recent US Food and Drug Admini ...... : just the tip of the iceberg?
@en
P2093
Anna S Lok
Jay H Hoofnagle
Norah Terrault
Paul Martin
Robert P Perrillo
P2860
P304
P356
10.1002/HEP.27609
P407
P577
2015-02-01T00:00:00Z